Streetbeat News

Stock Prices

ANF

Abercrombie & Fitch has revised its FY24 net sales growth outlook to approximately 10%, up from the previous forecast of 4% to 6%.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:33 am

ANF

Abercrombie & Fitch shares are trading higher following better-than-expected Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:32 am

ANF

Abercrombie & Fitch (NYSE:ANF) reported strong Q1 results with adjusted earnings per share (EPS) of $2.14, beating the analyst estimate of $1.73 by 23.7%. Sales reached $1.02 billion, surpassing the $963.26 million estimate and marking a 22.01% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:31 am

OZK

Bank OZK shares are trading lower following a downgrade from Citigroup, which changed its rating from Buy to Sell and reduced the price target from $57 to $37.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:28 am

VIK

Viking Holdings shares are trading lower after the company reported Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:27 am

AXSM

Axsome Therapeutics will present data on Solriamfetol, showing cognitive improvements, at the SLEEP 2024 conference.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:25 am

ASRT

Assertio has appointed Brendan P. O'Grady as the new Chief Executive Officer and a member of the Board, effective May 29, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:25 am

BITF

Trading halt status was updated at 7:25:00 AM ET, with details on quotation resumption and news resumption times.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:25 am

SRDX

Surmodics has entered into a definitive agreement to be acquired by private equity firm GTCR for $43.00 per share in cash, valuing the company at approximately $627 million. The acquisition price represents a 41.1% premium to Surmodics' 30-day volume-weighted average closing price. The Board of Directors has unanimously approved the transaction and recommends stockholders vote in favor. Post-transaction, Surmodics will become a privately held company and its stock will be delisted from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:22 am

RPTX

Repare Therapeutics Inc. (NASDAQ:RPTX) announced that initial data from its Phase 1 MINOTAUR study on lunresertib (RP-6306) in combination with FOLFIRI for advanced solid tumors will be presented at the ESMO GI Cancers Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

May 29, 2024 | 11:19 am